AP3B1

Summary

AP3B1 (adaptor related protein complex 3 subunit beta 1, HGNC:566) is a protein-coding gene on chromosome 5q14.1, encoding AP-3 complex subunit beta-1 (O00203). Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes.

This gene encodes a protein that may play a role in organelle biogenesis associated with melanosomes, platelet dense granules, and lysosomes. The encoded protein is part of the heterotetrameric AP-3 protein complex which interacts with the scaffolding protein clathrin. Mutations in this gene are associated with Hermansky-Pudlak syndrome type 2. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 8546 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Hermansky-Pudlak syndrome 2 (Definitive, ClinGen)
• GWAS associations: 18
• Clinical variants (ClinVar): 1,000 total — 45 pathogenic, 28 likely-pathogenic
• Phenotypes (HPO): 47
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003664

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:566
Approved symbol	AP3B1
Name	adaptor related protein complex 3 subunit beta 1
Location	5q14.1
Locus type	gene with protein product
Status	Approved
Aliases	ADTB3A, HPS2
Ensembl gene	ENSG00000132842
Ensembl biotype	protein_coding
OMIM	603401
Entrez	8546

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 21 protein_coding, 6 nonsense_mediated_decay, 4 retained_intron, 4 protein_coding_CDS_not_defined

ENST00000255194, ENST00000517561, ENST00000517940, ENST00000519295, ENST00000519888, ENST00000520122, ENST00000522901, ENST00000523204, ENST00000695447, ENST00000695448, ENST00000695449, ENST00000695450, ENST00000695451, ENST00000695452, ENST00000695453, ENST00000695454, ENST00000695455, ENST00000695458, ENST00000695488, ENST00000695505, ENST00000695506, ENST00000695507, ENST00000695510, ENST00000695511, ENST00000695512, ENST00000695513, ENST00000695514, ENST00000695515, ENST00000695540, ENST00000909857, ENST00000909858, ENST00000913629, ENST00000913630, ENST00000913631, ENST00000959993

RefSeq mRNA: 3 — MANE Select: NM_003664 NM_001271769, NM_001410752, NM_003664

CCDS: CCDS4041, CCDS64186, CCDS93737

Canonical transcript exons

ENST00000255194 — 27 exons

Exon	Start	End
ENSE00000971647	78020692	78020789
ENSE00000971648	78015410	78015548
ENSE00001004976	78141143	78141319
ENSE00001004980	78116126	78116234
ENSE00001162621	78156258	78156367
ENSE00001162627	78162819	78162951
ENSE00002117807	78294452	78294698
ENSE00003491648	78034361	78034445
ENSE00003500093	78128030	78128160
ENSE00003524684	78113752	78113923
ENSE00003551949	78129121	78129307
ENSE00003605513	78089393	78089499
ENSE00003614414	78100953	78101025
ENSE00003623425	78039043	78039274
ENSE00003672382	78110207	78110354
ENSE00003964102	78267520	78267595
ENSE00003964103	78228144	78228239
ENSE00003964104	78216055	78216237
ENSE00003964105	78175784	78175838
ENSE00003964106	78175626	78175697
ENSE00003964108	78240862	78240936
ENSE00003964109	78181507	78181662
ENSE00003964111	78225542	78225608
ENSE00003964112	78165610	78165672
ENSE00003964113	78227372	78227532
ENSE00003964114	78177339	78177436
ENSE00003964224	78002326	78003055

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 97.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.6475 / max 482.0866, expressed in 1818 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62203	36.1381	1817
62201	2.2225	1164
62202	0.7221	441
62196	0.4776	73
62197	0.0873	13

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	97.01	gold quality
calcaneal tendon	UBERON:0003701	95.27	gold quality
tendon	UBERON:0000043	94.93	gold quality
islet of Langerhans	UBERON:0000006	94.03	gold quality
adenohypophysis	UBERON:0002196	93.82	gold quality
pituitary gland	UBERON:0000007	93.81	gold quality
monocyte	CL:0000576	93.78	gold quality
mononuclear cell	CL:0000842	93.51	gold quality
leukocyte	CL:0000738	93.32	gold quality
rectum	UBERON:0001052	92.49	gold quality
olfactory bulb	UBERON:0002264	92.25	gold quality
stromal cell of endometrium	CL:0002255	91.65	gold quality
type B pancreatic cell	CL:0000169	91.59	gold quality
mucosa of transverse colon	UBERON:0004991	91.44	gold quality
smooth muscle tissue	UBERON:0001135	91.24	gold quality
lower esophagus mucosa	UBERON:0035834	91.22	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.21	gold quality
adrenal tissue	UBERON:0018303	91.20	gold quality
esophagus mucosa	UBERON:0002469	91.17	gold quality
pancreas	UBERON:0001264	90.98	gold quality
minor salivary gland	UBERON:0001830	90.88	gold quality
left lobe of thyroid gland	UBERON:0001120	90.81	gold quality
descending thoracic aorta	UBERON:0002345	90.80	gold quality
medial globus pallidus	UBERON:0002477	90.69	gold quality
body of pancreas	UBERON:0001150	90.68	gold quality
right lobe of thyroid gland	UBERON:0001119	90.52	gold quality
corpus epididymis	UBERON:0004359	90.42	gold quality
popliteal artery	UBERON:0002250	90.23	gold quality
tibial artery	UBERON:0007610	90.23	gold quality
adult mammalian kidney	UBERON:0000082	90.19	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.29

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, CEBPB, CREBZF, NFKB, TFAP2A, TP53, ZKSCAN7, ZNF91

miRNA regulators (miRDB)

70 targeting AP3B1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-3660	99.68	67.33	1149
HSA-MIR-4526	99.68	67.07	1136
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-6715B-5P	99.64	69.63	1420

Literature-anchored findings (GeneRIF, showing 16)

• Two nonsense mutations in ADTB3A, C1578T (R–>X) and G2028T (E–>X), result in lack of ADTB3A mRNA and beta3A protein production and a severe, G-CSF-responsive neutropenia in addition to oculocutaneous albinism and platelet storage pool deficiency. (PMID:11809908)
• Description of mutations in HPS genes that cause Hermansky-Pudlak syndrome (review) (PMID:12125811)
• We defined a homozygous genomic deletion in AP3B1, the gene encoding the beta chain of the adaptor protein-3 (AP-3) complex. The mutation leads to in-frame skipping of exon 15 and thus perturbs proper assembly of the heterotetrameric AP-3 complex. (PMID:16537806)
• A novel homozygous mutation in AP3B1 was detected in a 2-year-old patient with oculocutaneous albinism and immunodeficiency with Hermansky-Pudlak syndrome type II and eventual acute fatal hemophagocytic lymphohistiocytosis. (PMID:16551969)
• Mutations in AP3B1 is not associated with familial hemophagocytic lymphohistiocytosis (PMID:18000860)
• AP-1 and AP-3 are involved in the formation of distinct types of clathrin-coated vesicles, each of which is characterized by the incorporation of specific cargo membrane proteins (PMID:18410487)
• Experimental investigation of five specific genes, AP3B1, ATP6AP1, BLOC1S1, LAMP2, and RAB11A, has confirmed novel roles for these proteins in the proper initiation of macroautophagy in amino acid-starved fibroblasts. (PMID:19246570)
• The study provides a description of two unrelated individuals with Hermansky Pudlak syndrome type 2 associated with novel mutations in AP3B1. (PMID:19679886)
• diphosphoinositol pentakisphosphate-mediated pyrophosphorylation of AP3B1 modulates the interaction with Kif3A and, as a consequence, affects the release of HIV-1 virus-like particles. (PMID:19934039)
• Data indicate that RUN and FYVE domain protein Rabip4’(RUFY1) interacts specifically and directly with adaptor protein complex AP-3. (PMID:23144738)
• Using a co-affinity purification strategy, authors have identified the beta subunit of the AP-3 adapter protein complex, AP3B1, as a binding partner for the M proteins of the zoonotic paramyxoviruses Nipah virus and Hendra virus. (PMID:25210190)
• Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis. (PMID:25980904)
• point mutation c.2702C>G in exon 23 of the AP3B1 gene caused deletion of 112 bp in the mRNA in two siblings. This mutation activates a cryptic donor splice site that overrules the wild-type donor splice site of this exon. Three other novel mutations in AP3B1 were identified, that is, a nonsense mutation c.716G>A (p.Trp239Ter), a 1-bp and a 4-bp deletion c.177delA and c.1839_1842delTAGA, respectively (PMID:28585318)
• data show that defects in adaptor protein complex 3-dependent maturation of Weibel-Palade bodies impairs exocytosis by affecting the recruitment of VAMP8. (PMID:30630984)
• Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. (PMID:33867526)
• HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. (PMID:34637926)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ap3b1a	ENSDARG00000100082
danio_rerio		ENSDARG00000110056
mus_musculus	Ap3b1	ENSMUSG00000021686
rattus_norvegicus	Ap3b1	ENSRNOG00000010624
drosophila_melanogaster	rb	FBGN0003210
caenorhabditis_elegans	apb-3	WBGENE00000163

Paralogs (4): AP2B1 (ENSG00000006125), AP1B1 (ENSG00000100280), AP3B2 (ENSG00000103723), AP4B1 (ENSG00000134262)

Protein

Protein identifiers

AP-3 complex subunit beta-1 — O00203 (reviewed: O00203)

Alternative names: Adaptor protein complex AP-3 subunit beta-1, Adaptor-related protein complex 3 subunit beta-1, Beta-3A-adaptin, Clathrin assembly protein complex 3 beta-1 large chain

All UniProt accessions (21): A0A0S2Z4Z4, A0A0S2Z5J4, A0A8Q3SHP3, A0A8Q3SHR2, A0A8Q3SHS3, A0A8Q3SHS6, A0A8Q3SHU2, A0A8Q3SHV5, A0A8Q3SHW6, A0A8Q3SHX0, A0A8Q3SI03, A0A8Q3SIM7, A0A8Q3SIS1, O00203, A0A8Q3WKF8, A0A8Q3WKI5, A0A8Q3WKJ9, A0A8Q3WKK0, A0A8Q3WKN2, A0A8Q3WL34, H0YBD0

UniProt curated annotations — full annotation on UniProt →

Function. Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals.

Subunit / interactions. Adaptor protein complex 3 (AP-3) is a heterotetramer composed of two large adaptins (delta-type subunit AP3D1 and beta-type subunit AP3B1 or AP3B2), a medium adaptin (mu-type subunit AP3M1 or AP3M2) and a small adaptin (sigma-type subunit APS1 or AP3S2). AP-3 associates with the BLOC-1 complex. Interacts with KIF3A; interaction is direct; interaction is impaired by pyrophosphorylation of AP3B1.

Subcellular location. Cytoplasmic vesicle. Clathrin-coated vesicle membrane. Golgi apparatus.

Tissue specificity. Ubiquitously expressed.

Post-translational modifications. Phosphorylated on serine residues. Pyrophosphorylation by 5-diphosphoinositol pentakisphosphate (5-IP7) impairs interaction with KIF3A. Serine pyrophosphorylation is achieved by Mg(2+)-dependent, but enzyme independent transfer of a beta-phosphate from a inositol pyrophosphate to a pre-phosphorylated serine residue.

Disease relevance. Hermansky-Pudlak syndrome 2 (HPS2) [MIM:608233] A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS. HPS2 differs from the other forms of HPS in that it includes immunodeficiency in its phenotype and patients with HPS2 have an increased susceptibility to infections. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the adaptor complexes large subunit family.

Isoforms (2)

UniProt ID	Names	Canonical?
O00203-1	1	yes
O00203-3	2

RefSeq proteins (3): NP_001258698, NP_001397681, NP_003655* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002553	Clathrin/coatomer_adapt-like_N	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR015151	B-adaptin_app_sub_C	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR026739	AP_beta	Family
IPR026740	AP3_beta	Family
IPR029390	AP3B_C	Domain
IPR029394	AP3B1_Ser	Domain
IPR056314	AP3B1/2_C	Domain

Pfam: PF01602, PF14796, PF14797, PF24080

UniProt features (24 total): compositionally biased region 9, modified residue 4, region of interest 3, sequence variant 3, sequence conflict 3, chain 1, splice variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9C5C	ELECTRON MICROSCOPY	3.6
9C5A	ELECTRON MICROSCOPY	4.2
9C59	ELECTRON MICROSCOPY	4.3
9C5B	ELECTRON MICROSCOPY	4.5
9C58	ELECTRON MICROSCOPY	4.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00203-F1	75.85	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 276, 609, 750, 752

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-432722	Golgi Associated Vesicle Biogenesis
R-HSA-6802952	Signaling by BRAF and RAF1 fusions
R-HSA-1643685	Disease
R-HSA-199991	Membrane Trafficking
R-HSA-199992	trans-Golgi Network Vesicle Budding
R-HSA-5653656	Vesicle-mediated transport
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers
R-HSA-6802957	Oncogenic MAPK signaling

MSigDB gene sets: 492 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_SINGLE_FERTILIZATION, GOBP_SYNAPTIC_VESICLE_LOCALIZATION, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, GOBP_EPITHELIUM_DEVELOPMENT, TAATAAT_MIR126, GOBP_RESPIRATORY_GASEOUS_EXCHANGE_BY_RESPIRATORY_SYSTEM, GOBP_AXO_DENDRITIC_TRANSPORT, GOBP_LYSOSOMAL_TRANSPORT, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_VACUOLE_ORGANIZATION, GOBP_VESICLE_LOCALIZATION

GO Biological Process (36): cell morphogenesis (GO:0000902), toll-like receptor signaling pathway (GO:0002224), hematopoietic progenitor cell differentiation (GO:0002244), respiratory system process (GO:0003016), protein targeting to lysosome (GO:0006622), intracellular zinc ion homeostasis (GO:0006882), intracellular protein transport (GO:0006886), inflammatory response (GO:0006954), lysosome organization (GO:0007040), spermatogenesis (GO:0007283), single fertilization (GO:0007338), blood coagulation (GO:0007596), anterograde axonal transport (GO:0008089), vesicle-mediated transport (GO:0016192), granulocyte differentiation (GO:0030851), melanosome organization (GO:0032438), protein localization to cell surface (GO:0034394), clathrin-coated vesicle cargo loading, AP-3-mediated (GO:0035654), mRNA transcription by RNA polymerase II (GO:0042789), positive regulation of transcription by RNA polymerase II (GO:0045944), antigen processing and presentation, exogenous lipid antigen via MHC class Ib (GO:0048007), anterograde synaptic vesicle transport (GO:0048490), homeostasis of number of cells (GO:0048872), positive regulation of NK T cell differentiation (GO:0051138), platelet dense granule organization (GO:0060155), lung morphogenesis (GO:0060425), obsolete establishment of protein localization to mitochondrial membrane involved in mitochondrial fission (GO:0090152), skin epidermis development (GO:0098773), melanosome assembly (GO:1903232), protein targeting (GO:0006605), gene expression (GO:0010467), protein transport (GO:0015031), antigen processing and presentation (GO:0019882), lung development (GO:0030324), pigmentation (GO:0043473), membrane organization (GO:0061024)

GO Molecular Function (4): protein phosphatase binding (GO:0019903), GTP-dependent protein binding (GO:0030742), protein binding (GO:0005515), clathrin binding (GO:0030276)

GO Cellular Component (13): mitochondrion (GO:0005739), lysosomal membrane (GO:0005765), early endosome (GO:0005769), Golgi apparatus (GO:0005794), membrane (GO:0016020), AP-3 adaptor complex (GO:0030123), clathrin adaptor complex (GO:0030131), clathrin-coated vesicle membrane (GO:0030665), axon cytoplasm (GO:1904115), microvesicle (GO:1990742), endomembrane system (GO:0012505), membrane coat (GO:0030117), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
trans-Golgi Network Vesicle Budding	1
Oncogenic MAPK signaling	1
Vesicle-mediated transport	1
Membrane Trafficking	1
Disease	1
Diseases of signal transduction by growth factor receptors and second messengers	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
intracellular protein localization	2
transcription by RNA polymerase II	2
protein binding	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
AP-type membrane coat adaptor complex	2
anatomical structure morphogenesis	1
pattern recognition receptor signaling pathway	1
hemopoiesis	1
cell differentiation	1
system process	1
respiratory gaseous exchange by respiratory system	1
protein targeting to vacuole	1
lysosomal transport	1
protein localization to lysosome	1
intracellular monoatomic cation homeostasis	1
inorganic ion homeostasis	1
protein transport	1
intracellular transport	1
defense response	1
lytic vacuole organization	1
developmental process involved in reproduction	1
male gamete generation	1
fertilization	1
hemostasis	1
wound healing	1
coagulation	1
axonal transport	1
axon cytoplasm	1
transport	1
cellular process	1
myeloid leukocyte differentiation	1
pigment granule organization	1
clathrin-coated vesicle cargo loading	1
mRNA transcription	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
phosphatase binding	1
binding	1

Protein interactions and networks

STRING

2054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AP3B1	HPS4	Q9NQG7	934
AP3B1	AP3D1	O14617	929
AP3B1	HPS3	Q969F9	925
AP3B1	AP3S1	Q92572	895
AP3B1	AP3M1	Q9Y2T2	889
AP3B1	HPS6	Q86YV9	841
AP3B1	BLOC1S3	Q6QNY0	836
AP3B1	HPS5	Q9UPZ3	825
AP3B1	LYST	Q99698	797
AP3B1	BHLHE22	Q8NFJ8	728
AP3B1	BLOC1S6	Q9UL45	724
AP3B1	UNC13D	Q70J99	720
AP3B1	STX11	O75558	720
AP3B1	STXBP2	Q15833	720
AP3B1	DTNBP1	Q96EV8	719

IntAct

203 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
AP3M1	AP3B1	psi-mi:“MI:0914”(association)	0.640
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
DNALI1	AP3B1	psi-mi:“MI:0915”(physical association)	0.560
BAG6	AP3B1	psi-mi:“MI:0915”(physical association)	0.560
OPTN	AP3B1	psi-mi:“MI:0915”(physical association)	0.560
AP3B1	ALS2	psi-mi:“MI:0915”(physical association)	0.560
AP3B1	SNCA	psi-mi:“MI:0915”(physical association)	0.560
AP3B1	HTT	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (270): AP3B1 (Co-localization), AP3B1 (Affinity Capture-Western), LRSAM1 (Affinity Capture-Western), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), AP3B1 (Co-fractionation), AP3B1 (Co-fractionation)

ESM2 similar proteins: A0A3Q1LSX9, A1A5G0, A1A5K2, A2A5R2, A2APV2, A2VE70, D3ZYR1, O00203, O04376, O35643, O60308, O75122, P52303, Q05397, Q08AM6, Q08DS7, Q0JRZ9, Q10567, Q13367, Q28FH2, Q32PG1, Q3UQN2, Q4U0G1, Q561M0, Q5R807, Q5ZIW5, Q6NUP7, Q6NXC0, Q6NYW6, Q6ZPF4, Q7TSU1, Q7YRF1, Q7Z460, Q80TV8, Q8BRT1, Q8C0Y0, Q8IVF7, Q8LF36, Q8N7B6, Q8RW96

Diamond homologs: O00203, O13939, O81742, Q13367, Q32PG1, Q54X82, Q556J8, Q7YRF1, Q9JME5, Q9M2T1, Q9SUS3, Q9Z1T1, O35643, O43005, O43079, P27351, P36000, P52303, P62944, P63009, P63010, Q08DS7, Q10567, Q9DBG3, Q9LDK9, Q9WV76, Q9Y6B7

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
AP3B1	“form complex”	“AP-3 complex”	binding
AP3B1	“up-regulates activity”	KIF3A	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 163 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neurexins and neuroligins	8	14.9×	4e-05
Signaling by NOTCH	6	9.9×	7e-03
ESR-mediated signaling	7	8.5×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
integrated stress response signaling	5	26.0×	2e-03
positive regulation of miRNA transcription	6	12.9×	4e-03
negative regulation of canonical NF-kappaB signal transduction	7	8.9×	4e-03
positive regulation of gene expression	14	4.0×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

1000 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	45
Likely pathogenic	28
Uncertain significance	455
Likely benign	344
Benign	52

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1071422	NM_003664.5(AP3B1):c.1619dup (p.Ala541fs)	Pathogenic
1072382	NM_003664.5(AP3B1):c.2694_2712del (p.Met899fs)	Pathogenic
1370969	NM_003664.5(AP3B1):c.2738del (p.Lys913fs)	Pathogenic
1416408	NM_003664.5(AP3B1):c.237_238del (p.Phe80fs)	Pathogenic
1451475	NM_003664.5(AP3B1):c.2757del (p.Ile919fs)	Pathogenic
1455598	NM_003664.5(AP3B1):c.2801del (p.Asn934fs)	Pathogenic
1456202	NM_003664.5(AP3B1):c.1101dup (p.Phe368fs)	Pathogenic
1878314	NM_003664.5(AP3B1):c.1789dup (p.Ile597fs)	Pathogenic
2019152	NM_003664.5(AP3B1):c.778del (p.Trp260fs)	Pathogenic
2030913	NM_003664.5(AP3B1):c.1255C>T (p.Gln419Ter)	Pathogenic
224760	NM_003664.5(AP3B1):c.2702C>G (p.Ser901Cys)	Pathogenic
224761	NM_003664.5(AP3B1):c.1754del (p.Val585fs)	Pathogenic
224762	NM_003664.5(AP3B1):c.716G>A (p.Trp239Ter)	Pathogenic
224763	NM_003664.5(AP3B1):c.177del (p.Lys59fs)	Pathogenic
224764	NM_003664.4(AP3B1):c.1839_1842delTAGA	Pathogenic
2503438	NM_003664.5(AP3B1):c.364C>T (p.Arg122Ter)	Pathogenic
2676731	NM_003664.5(AP3B1):c.1363+1G>A	Pathogenic
2698780	NM_003664.5(AP3B1):c.1973_1983dup (p.Pro662fs)	Pathogenic
2705668	NM_003664.5(AP3B1):c.753T>G (p.Tyr251Ter)	Pathogenic
2717774	NM_003664.5(AP3B1):c.2675_2679del (p.Pro892fs)	Pathogenic
2739632	NM_003664.5(AP3B1):c.2734C>T (p.Arg912Ter)	Pathogenic
2748816	NM_003664.5(AP3B1):c.1408del (p.Gln470fs)	Pathogenic
2749771	NM_003664.5(AP3B1):c.1930_1937del (p.Pro644fs)	Pathogenic
2812558	NM_003664.5(AP3B1):c.1907T>G (p.Leu636Ter)	Pathogenic
2837529	NM_003664.5(AP3B1):c.1286del (p.Gly429fs)	Pathogenic
3239621	GRCh37/hg19 5q14.1(chr5:77396777-77396849)x1	Pathogenic
3246334	NC_000005.9:g.(?77590256)(77590403_?)del	Pathogenic
3653778	NM_003664.5(AP3B1):c.624dup (p.Met209fs)	Pathogenic
3897901	NM_003664.5(AP3B1):c.2514_2515del (p.Pro840fs)	Pathogenic
3910635	NM_003664.5(AP3B1):c.2249+1del	Pathogenic

SpliceAI

6053 predictions. Top by Δscore:

Variant	Effect	Δscore
5:78003057:T:A	acceptor_loss	1.0000
5:78015546:CTC:C	acceptor_gain	1.0000
5:78015549:C:CC	acceptor_gain	1.0000
5:78017414:A:AC	donor_gain	1.0000
5:78017415:G:C	donor_gain	1.0000
5:78019512:A:T	acceptor_gain	1.0000
5:78020788:TA:T	acceptor_gain	1.0000
5:78020790:C:CC	acceptor_gain	1.0000
5:78034359:A:AC	donor_gain	1.0000
5:78034360:C:CC	donor_gain	1.0000
5:78034360:CCA:C	donor_gain	1.0000
5:78034446:C:CC	acceptor_gain	1.0000
5:78039270:CTGAC:C	acceptor_gain	1.0000
5:78039286:G:T	acceptor_gain	1.0000
5:78089391:A:AC	donor_gain	1.0000
5:78089392:C:CC	donor_gain	1.0000
5:78089392:CA:C	donor_gain	1.0000
5:78089497:TAA:T	acceptor_gain	1.0000
5:78089500:C:CC	acceptor_gain	1.0000
5:78100943:CAATA:C	donor_gain	1.0000
5:78100945:ATACT:A	donor_loss	1.0000
5:78100946:TACTT:T	donor_loss	1.0000
5:78100947:A:AC	donor_gain	1.0000
5:78100947:ACT:A	donor_loss	1.0000
5:78100948:C:CC	donor_gain	1.0000
5:78100948:C:G	donor_loss	1.0000
5:78100949:TT:T	donor_loss	1.0000
5:78100950:T:TG	donor_loss	1.0000
5:78100951:A:AC	donor_gain	1.0000
5:78100951:A:C	donor_loss	1.0000

AlphaMissense

7228 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:78129240:C:G	R573P	1.000
5:78141177:A:G	L539P	1.000
5:78175818:A:G	L354P	1.000
5:78216123:C:G	G240R	1.000
5:78216123:C:T	G240R	1.000
5:78216124:C:A	W239C	1.000
5:78216124:C:G	W239C	1.000
5:78216126:A:G	W239R	1.000
5:78216126:A:T	W239R	1.000
5:78216223:A:C	S206R	1.000
5:78216223:A:T	S206R	1.000
5:78216225:T:G	S206R	1.000
5:78216227:C:T	G205D	1.000
5:78225558:A:G	L196P	1.000
5:78225561:A:G	L195P	1.000
5:78227391:C:G	A173P	1.000
5:78227396:G:T	A171D	1.000
5:78227400:C:G	A170P	1.000
5:78227404:C:A	K168N	1.000
5:78227404:C:G	K168N	1.000
5:78227407:C:A	R167S	1.000
5:78227407:C:G	R167S	1.000
5:78227408:C:A	R167M	1.000
5:78227408:C:G	R167T	1.000
5:78227409:T:A	R167W	1.000
5:78227411:A:T	V166D	1.000
5:78227468:A:T	I147N	1.000
5:78227492:A:G	L139P	1.000
5:78227504:G:T	A135D	1.000
5:78227505:C:G	A135P	1.000

dbSNP variants (sampled 300 via entrez): RS1000005033 (5:78038786 C>A,T), RS1000033267 (5:78135386 A>C), RS1000048293 (5:78274453 G>C), RS1000052093 (5:78035096 G>A,T), RS1000055365 (5:78281052 T>C,G), RS1000079189 (5:78274800 C>T), RS1000105623 (5:78087219 G>C,T), RS1000108289 (5:78185794 C>T), RS1000129255 (5:78257629 C>A), RS1000137027 (5:78117040 A>C,G), RS1000137410 (5:78032020 G>T), RS1000141220 (5:78050030 C>G,T), RS1000153190 (5:78230568 T>G), RS1000158428 (5:78071374 C>T), RS1000177799 (5:78215355 T>G)

Disease associations

OMIM: gene MIM:603401 | disease phenotypes: MIM:608233, MIM:203300

GenCC curated gene-disease

Disease	Classification	Inheritance
Hermansky-Pudlak syndrome 2	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Hermansky-Pudlak syndrome 2	Definitive	AR

Mondo (7): Hermansky-Pudlak syndrome 2 (MONDO:0011997), autoinflammatory syndrome (MONDO:0019751), prostate cancer (MONDO:0008315), Hermansky-Pudlak syndrome (MONDO:0019312), combined immunodeficiency (MONDO:0015131), thrombocytopenia (MONDO:0002049), intellectual disability (MONDO:0001071)

Orphanet (7): Hermansky-Pudlak syndrome due to AP-3 deficiency (Orphanet:183678), Hermansky-Pudlak syndrome (Orphanet:79430), Autoinflammatory syndrome (Orphanet:93665), Familial prostate cancer (Orphanet:1331), Combined T and B cell immunodeficiency (Orphanet:101972), Hermansky-Pudlak syndrome due to AP3B1 deficiency (Orphanet:664500), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

47 total (30 of 47 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000280	Coarse facial features
HP:0000286	Epicanthus
HP:0000319	Smooth philtrum
HP:0000343	Long philtrum
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000403	Recurrent otitis media
HP:0000431	Wide nasal bridge
HP:0000486	Strabismus
HP:0000582	Upslanted palpebral fissure
HP:0000613	Photophobia
HP:0000639	Nystagmus
HP:0000666	Horizontal nystagmus
HP:0000670	Carious teeth
HP:0000704	Periodontitis
HP:0001022	Albinism
HP:0001107	Ocular albinism
HP:0001256	Mild intellectual disability
HP:0001270	Motor delay
HP:0001433	Hepatosplenomegaly
HP:0001744	Splenomegaly
HP:0001873	Thrombocytopenia
HP:0001875	Decreased total neutrophil count
HP:0002020	Gastroesophageal reflux
HP:0002206	Pulmonary fibrosis
HP:0002240	Hepatomegaly
HP:0002286	Fair hair

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST001208_9	Insulin resistance/response	6.000000e-07
GCST003301_5	Triglycerides	7.000000e-08
GCST006481_8	Lung function (FEV1)	6.000000e-09
GCST006483_19	Lung function (FVC)	2.000000e-11
GCST006483_52	Lung function (FVC)	3.000000e-11
GCST006483_53	Lung function (FVC)	3.000000e-11
GCST007429_52	Lung function (FVC)	3.000000e-14
GCST007432_138	FEV1	7.000000e-09
GCST008114_34	Type 2 diabetes	8.000000e-06
GCST009391_1660	Metabolite levels	2.000000e-07
GCST010483_4	Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment	8.000000e-06
GCST010988_94	Adult body size	2.000000e-09
GCST010989_252	Body size at age 10	4.000000e-11
GCST012227_1350	Hip circumference adjusted for BMI	8.000000e-15
GCST90000025_44	Appendicular lean mass	1.000000e-18
GCST90002404_210	Red cell distribution width	2.000000e-09
GCST90011900_104	Serum alkaline phosphatase levels	3.000000e-08
GCST90013406_139	Liver enzyme levels (alkaline phosphatase)	3.000000e-13

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004314	forced expiratory volume
EFO:0004312	vital capacity
EFO:0010470	carnosine measurement
EFO:0006919	cardiovascular event measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0008039	BMI-adjusted hip circumference
EFO:0004980	appendicular lean mass
EFO:0009188	Red cell distribution width
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D022861	Hermanski-Pudlak Syndrome	C11.270.040.545.400; C15.378.100.100.515; C15.378.100.685.400; C15.378.140.735.400; C15.378.463.735.400; C16.320.099.515; C16.320.290.040.100.400; C16.320.565.100.102.100.400; C16.320.850.080.100.400; C17.800.621.440.102.100.400; C17.800.827.080.100.400; C18.452.648.100.102.100.400
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937
C537709	Hermansky Pudlak syndrome 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724792 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.31	Kd	49.02	nM	CHEMBL5653589
7.31	ED50	49.02	nM	CHEMBL5653589
7.30	Kd	50	nM	MOLIBRESIB
7.10	IC50	80	nM	MOLIBRESIB
6.25	Kd	557.6	nM	CHEMBL3752910
6.25	ED50	557.6	nM	CHEMBL3752910

PubChem BioAssay actives

4 with measured affinity, of 11 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147868: Binding affinity to human AP3B1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0490	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179179: Binding affinity against AP3B1 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0500	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147868: Binding affinity to human AP3B1 incubated for 45 mins by Kinobead based pull down assay	kd	0.5576	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression	3
sodium arsenite	increases expression, decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
terbufos	decreases methylation	1
beta-lapachone	increases expression	1
arsenite	decreases expression, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
bisphenol AF	increases expression	1
Fulvestrant	decreases reaction, decreases expression	1
Arsenic	decreases expression, increases abundance	1
Cadmium	decreases expression, decreases reaction	1
Cannabidiol	increases expression	1
Clozapine	increases expression	1
Fonofos	decreases methylation	1
Estradiol	decreases expression, decreases reaction	1
Haloperidol	increases expression	1
Ivermectin	decreases expression	1
Parathion	decreases methylation	1
Ribonucleotides	affects binding	1
Vanadates	increases expression	1
tert-Butylhydroperoxide	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5650910	Binding	Binding affinity to human AP3B1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

3 cell lines: 2 induced pluripotent stem cell, 1 finite cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0R47	GM17890	Finite cell line	Male
CVCL_A0JY	SANi009-A	Induced pluripotent stem cell	Female
CVCL_DQ89	CHOPHPS2	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer